Egypt’s Cleopatra Hospitals bid to buy Alameda Healthcare halted

The proposed deal was originally announced by Cleopatra in late December 2020

  
A doctor examines a pregnant woman at a hospital in the province of Fayoum, southwest of Cairo, Egypt February 19, 2019. Image for illustrative purposes.

A doctor examines a pregnant woman at a hospital in the province of Fayoum, southwest of Cairo, Egypt February 19, 2019. Image for illustrative purposes.

REUTERS/Hayam Adel
 
RIYADH: Egypt’s Cleopatra Hospitals Group said its bid to acquire Alameda Healthcare through a sale and purchase agreement of shares has been halted.

It made the disclosure in a filing to the Egyptian Stock Exchange on Monday.

The proposed deal was originally announced by Cleopatra in late December 2020, with an estimated value of about $500 million.

But it was quickly followed by an announcement from the Egyptian Competition Authority saying that it did not agree in principle to the acquisition.

It highlighted the potential consolidation of Cleopatra’s dominance over hospitals around Cairo and Giza.

Alameda Healthcare’s network includes four tertiary care hospitals in Cairo, two of which are currently being constructed. Once the facilities are fully commissioned Alameda Healthcare will have a capacity of 890 beds, according to its website. The network also includes facilities in Kuwait and London, outpatient clinics, diagnostic centers, specialist centers, pharmacies, and a rehabilitation center.

Copyright: Arab News © 2021 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Equities